Flucytosine and cryptococcosis: Time to urgently address the worldwide accessibility of a 50-year-old antifungal

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 11, 2013, Pages 2435-2444

  Loyse, Angela ^a   Dromer, Françoise ^b,c   Day, Jeremy ^d   Lortholary, Olivier ^b,c,e   Harrison, Thomas S ^a  

^a Life Sciences   (United Kingdom)

^b INSTITUT PASTEUR   (France)

^c CNRS   (France)

^d OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

5 FC; 5 FC safety; Access to essential antifungals for cryptococcal meningitis; Combination antifungal therapy; Cryptococcal meningitis; Cryptococcal meningitis treatment guidelines; Opportunistic infection

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; AREA UNDER THE CURVE; ARTICLE; CREATININE CLEARANCE; CRYPTOCOCCOSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

5-FC; 5-FC SAFETY; ACCESS TO ESSENTIAL ANTIFUNGALS FOR CRYPTOCOCCAL MENINGITIS; COMBINATION ANTIFUNGAL THERAPY; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCAL MENINGITIS TREATMENT GUIDELINES; OPPORTUNISTIC INFECTION;

AFRICA; AIDS-RELATED OPPORTUNISTIC INFECTIONS; AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASIA; FLUCONAZOLE; FLUCYTOSINE; HIV INFECTIONS; HUMANS; MENINGITIS, CRYPTOCOCCAL;

EID: 84886289843     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt221     Document Type: Article

References (89)

1. Duchinsky R, Pleven E, Heidelberger C. The synthesis of 5-fluoropyrimidines. J AmChem Soc 1957; 79: 4559-60.
2. Heidelberger C, Griesbach L, Montag B et al. Studies on fluorinated pyrimidines. Effects on transplanted tumours. Cancer Res 1958; 18: 305-17.
3. Grunberg E, Titsworth E, Bennett M. Chemotherapeutic activity of 5-fluorocytosine. Antimicrob Agents Chemother 1963; 3: 566-8.
4. Tassel D, Madoff MA. Treatment of Candida sepsis and Cryptococcus meningitis with 5-fluorocytosine. A new antifungal agent. JAMA 1968; 206: 830-2.
5. Block ER, Bennett JE. Pharmacological studies with 5-fluorocytosine. Antimicrob Agents Chemother 1972; 1: 476-82.
6. Vermes A, Guchelaar H-J, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 2000; 46: 171-9.
7. Lopes CF, Cisalpino EO, Alvarenjo RJ et al. Treatment of chromomycosis with 5-fluorocytosine. Int J Dermatol 1971; 10: 182-91.
8. Stevens AR, O'Dell WD. In vitro and in vivo activity of 5-fluorocytosine on Acanthamoeba. Antimicrob Agents Chemother 1974; 6: 182-91.
9. Benson JM, Nahata MC. Clinical use of systemic antifungal agents. Clin Pharm 1988; 7: 424-38.
10. Bennett JE. Flucytosine. Ann Intern Med 1977; 86: 319-21.
11. Polak A, Scholer HJ. Mode of action of 5-fluorocytosine. Rev Inst Pasteur Lyon 1980; 13: 233-44.
12. Groll AH, Gea-Banaloche JC, Glasmacher A et al. Clinical pharmacology of antifungal compounds. Infect Dis Clin North Am 2003; 17: 159-91.
13. Russell EL. Pharmacodynamic implications for use of antifungal agents. Curr Opin Pharmacol 2007; 7: 491-7.
14. Harris BE, ManningBW, FederleTW et al. Conversion of 5-fluorocytosine to 5-fluorouracil by human intestinal microflora. Antimicrob Agents Chemother 1986; 29: 44-8.
15. Diasio RB, Lakings DE, Bennett JE. Evidence for the conversion of 5-fluorocytosine to 5-fluouracil in humans: possible factor in 5-fluorocytosine clinical toxicity. Antimicrob Agents Chemother 1978; 14: 903-8.
16. Williams KM, Duffield AM, Christopher RK et al. Identification of minor metabolites of 5-fluorocytosine in man by chemical ionization gas chromatography mass spectrometry. Biochem Mass Spectrom 1981; 8: 179-82.17
17. Brouwer AE, van Kan HJ, Johnson E et al. Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis. AntimicrobAgentsChemother 2007;51:1038-42.
18. Heidelberger C. Pyrimidine and pyrimidine nucleoside antimetabolites. In: Holland JF, Frei E III, ed. Cancer Medicine. Philadelphia: Lee and Febiger, 1982.
19. Kauffman CA, Frame PT. Bone marrow toxicity associated with 5-fluorocytosine therapy. Antimicrob Agents Chemother 1977; 11: 244-7.
20. Scholer HJ. Flucytosine. In: Speller DCE, ed. Antifungal Chemotherapy. Chichester, UK: J. Wiley & Sons, 1980.
21. Polak A, Scholer HJ. Combination of amphotericin B and 5-fluorocytosine. In: Williams JD, Geddes AM, ed. Chemotherapy. Vol. 6, Parasites, fungi and viruses. New York: Plenum, 1976.
22. Malet-Martino MC, Martino Ret al. Flucytosine conversion to fluorouracil in humans: does a correlation with gut flora exist? A report of two cases using fluorine-19 magnetic resonance spectroscopy. Infection 1991; 19: 178-80.
23. Vermes A, Kuijper EJ, Guchelaar HJ, Dankert J. An in vitro study on the active microflora. Chemotherapy 2003; 49: 17-23.
24. Cutler RE, Blair AD, Kelly MR. Flucytosine kinetics in subjects with normal and impaired renal function. Clin Pharmacol Ther 1978; 24: 333-42.
25. Gurumurthy P, Ramachandran G, Kumar AKH et al. Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease. Antimicrob Agents Chemother 2004; 48: 4473-5.
26. Schonebeck J, Polak A, Fernex M et al. Pharmacokinetic studies on the oral antimycotic agent 5-fluorocytosine in individuals with normal and impaired kidney function. Chemotherapy 1973; 18: 321-36.
27. Francis P,Walsh TJ. Evolving role of flucytosine inimmunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clin Infect Dis 1992; 15: 1003-18.
28. Lewis RE, Klepser ME, Pfaller MA. In vitro pharmacodynamics characteristics of flucytosine determined by time-kill methods. Diagn Microbiol Infect Dis 2000; 36: 101-5.
29. Andes D, van Ogtrop M. In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model. Antimicrob Agents Chemother 2000; 44: 938-42.
30. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Testing of Yeasts-Second Edition. Approved Standard M27-A2. NCCLS,Wayne, PA, USA, 2002.
31. RexJH, Pfaller MA. Hasantifungal susceptibility testingcomeof age?Clin Infect Dis 2002; 35: 982-9.
32. Moore CB, Walls CM, Denning DW. Comparison of three methods for in vitro susceptibility testing of Candida species with flucytosine. J Antimicrob Chemother 2003; 51: 297-304.
33. Rex JH, Pfaller MA, Walsh TJ et al. Antifungal susceptibility testing: practicalaspectsandcurrent challenges. ClinMicrobiolRev2001;14: 643-58.
34. Dannaoui E, Abdul M, Arpin M et al. Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis. Antimicrob Agents Chemother 2006; 50: 2464-70.
35. Schwarz P, Dromer F, Lortholay O et al. In vitro interaction of flucytosine with conventional and new antifungals against Cryptococcus neoformans clinical isolates. Antimicrob Agents Chemother 2003; 47: 3361-4.
36. Armstrong D, Schmitt HJ. Older drugs. In: Ryley JF, ed. Chemotherapy for Fungal Diseases. Berlin: Springer-Verlag, 1990.
37. Chandenier JKD, Adou-Bryn C, Douchet C et al. In vitro activity of amphotericin B, fluconazole and voriconazole against 162 Cryptococcusneoformans isolates from Africa and Cambodia. Eur J Clin Microbiol Infect Dis 2004; 23: 506-8.
38. Scholer HJ, Polak A. Resistance to systemic antifungal agents. In: Bryan LE, ed. Antimicrobial Drug Resistance. Orlando, FL: Academic Press, 1984.
39. Brandt ME, Pfaller MA, Hajjeh RA et al. Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998. Antimicrob Agents Chemother 2001; 45: 3065-9.
40. Pfaller MA, Messer SA, Boyken L et al. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J Clin Microbiol 2005; 43: 2163-7.
41. Cuenca-Estrella M, Diaz-Guerra TM, Mellado E et al. Flucytosine primary resistance in Candida species and Cryptococcus neoformans. Eur J Clin Microbiol Infect Dis 2001; 45: 3065-9.
42. Calvo BM, Colombo AL, Fischman O et al. Antifungal susceptibilities, varieties and electrophoretic karyotypes of clinical isolates of Cryptococcus neoformans from Brazil, Chile and Venezuela. J Clin Microbiol 2001; 39: 2348-50.
43. Klepser ME, Pfaller MA. Variation in electrophoretic karyotype and antifungal susceptibility of clinical isolates of Cryptococcus neoformans at a university-affiliated teaching hospital from 1987 to 1994. J Clin Microbiol 1998; 36: 2817-22.
44. Abdel-Salam HA. In vitro susceptibility of Cryptococcus neoformans clinical isolates from Egypt to seven antifungal drugs. Mycoses 2005; 48: 327-32.
45. Polak A, Scholer HJ. Modeof action of 5-fluorocytosineandmechanisms of resistance. Chemotherapy 1975; 21: 113-30.
46. Polak A. 5-Fluorocytosine-current status with special references to mode of action and drug resistance. Contrib Microbiol Immunol 1977; 4: 158-67.
47. Schwarz P, Janbon J, Dromer Fet al. Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans. Antimicrob Agents Chemother 2007; 51: 383-5.
48. Schwarz P, Dromer F, LortholaryO, Dannaoui E. Efficacyof amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis. Antimicrob Agents Chemother 2006; 50: 113-20.
49. Polak A, Scholer HJ, Wall M. Combination therapy of experimental candidiasis, cryptococcosis and aspergillosis in mice. Chemotherapy 1982; 28: 461-79.
50. Polak A. Combination therapyof experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis in mice. Chemotherapy 1987; 33: 381-95.
51. Hamilton JD, Elliott DM. Combined activity of amphotericin B and 5-fluorocytosine against Cryptococcus neoformans in vitro and in vivo in mice. J Infect Dis 1975; 131: 129-37.
52. Diamond DM, Bauer DM, Daniel MA et al. Amphotericin B colloidal dispersion combined with flucytosine with or without fluconazole for treatment of murine cryptococcal meningitis. Antimicrob Agents Chemother 1998; 42: 528-33.
53. Ding JC, Bauer DM, DiamondDM et al. Effect of severity of meningitis on fungicidal activity of flucytosine combined with fluconazole in a murine model of cryptococcal meningitis. Antimicrob Agents Chemother 1997; 41: 1589-93.
54. Larsen RA, Bauer M,Weiner JM et al. Effect of fluconazole on fungicidal activity of flucytosine in murine cryptococcal meningitis. Antimicrob Agents Chemother 1996; 40: 2178-282.
55. Nguyen M.H.,Najvar LK, Yu C.Y. et al.Combination therapywithfluconazole and flucytosine in the murine model of cryptococcal meningitis. Antimicrob Agents Chemother 1997; 41: 1120-3.56
56. Kartalija M, Kaye K, Tureen JH et al. Treatment of experimental cryptococcal meningitis with fluconazole: impact of dose and addition of flucytosine on mycologic and pathophysiologic outcome. J Infect Dis 1996; 173: 1216-20.
57. Hospenthal DR, Bennett JE. Flucytosine monotherapy for cryptococcosis. Clin Infect Dis 1998; 27: 260-4.
58. Bennett JE, Dismukes WE,DumaRJ et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med 1979; 301: 126-31.
59. Dismukes WE, Cloud G, Gallis HA et al. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med 1987; 317: 334-41.
60. van der Horst CM, Saag MS, Cloud GA et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med 1997; 337: 15-21.
61. Saag MS, Cloud GA, Graybill R et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. Clin Infect Dis 1999; 28: 291-6.
62. Brouwer A, Rajanuwong A, Chierakul W et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 2004; 364: 1764-7.
63. Bicanic T, Muzoora C, Brouwer AE et al. Rate of clearance of infection is independently associated with clinical outcome in HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis 2009; 49: 702-9.
64. NussbaumJC, JacksonA,NamarikaD et al. Combination flucytosineand high dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomised trial in Malawi. Clin Infect Dis 2010; 50: 338-44.
65. Bicanic T, Jarvis J, Loyse A et al. Determinants of acute outcome and long-term survival in HIV-associated cryptococcal meningitis: results of a combined cohort of 523 patients. In: Abstracts of the 18th Conference on Retroviruses and Opportunistic Infections, Boston, February 2011. Abstract P-123.
66. Day JN, Tran TH, Chau et al. Combination antifungal therapy for HIV-associated cryptococcalmeningitis.NEngl JMed 2013; 368: 1291-302.
67. Loyse A, Wilson D, Meintjes G et al. Comparison of the early fungicidal activity of high dose fluconazole, the voriconazole, and flucytosine, as second drugs given in combination with amphotericin for the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis 2012; 54: 121-8.
68. Dromer F,Mathoulin-Pélissier S, LaunayOet al. Determinants of disease presentation and outcome during cryptococcosis: the Crypto A/D Study. PLoS Med 2007; 4:e21.
69. Dromer F, Bernede-Bauduin C, Guillemot D et al. Major role for amphotericin B-flucytosine combination in severe cryptococcosis. PLoS One 2008; 3 e2870: 1-9.
70. Larsen RA, Bozette SA, Jones BE et al. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1994; 19: 741-5.
71. Mayanja-Kizza H, Oishi K, Mitarai S et al. Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS. Clin Infect Dis 1998; 26: 1362-6.
72. Milfechik E, Leal MA, Haubrich R et al. Fluconazole alone or combined with flucytosine for the treatment of AIDS-associated cryptococcal meningitis. Med Mycol 2008; 46: 393-5.73
73. LongleyN, Muzoora C, Taseera K et al. Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. Clin Infect Dis 2008; 47: 1556-61.
74. Jarvis NJ, Meintjes G, Rebe K et al. Adjunctive interferon-g immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. AIDS 2012; 26: 1105-13.
75. Jackson AT, Nussbaum JC, Phulusa J et al. A phase II randomized controlled trial adding oral flucytosine to high dose fluconazole with short-course amphotericin B, for cryptococcal meningitis. AIDS 2012; 26: 1361-70.
76. Bicanic T, Wood R, Meintjes G et al. High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin Infect Dis 2008; 47: 123-30.
77. Perfect JR, Dismukes WE, Dromer F et al. 2010 IDSA guidelines. Practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2010; 50: 291-322.
78. Reich D, Nalls MA, Kao WHLet al. Reduced neutrophil count in people of African descent is due to a regulatory variant in the Duffy antigen receptor for chemokines gene. PLoS Genet 2009; 5: e1000360.
79. WHO. Rapid advice: diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children. Geneva: WHO, December 2011.
80. Park BJ, Wannemuehler KA, Marston BJ et al. Estimation of the global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009; 23: 525-30.
81. Mwaba P,Mwansa J, Chintu Cet al. Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions. Postgrad Med J 2001; 77: 769-73.
82. Schaars CF, Meintjes GA, Morroni C et al. Outcome of AIDS-associated cryptococcal meningitis initially treated with 200mg/day or 400mg/day of fluconazole. BMC Infect Dis 2006; 6: 118.
83. Bicanic T, Meintjes G, Wood R et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis 2007; 45: 76-80.
84. Kambugu A, Meya DB, Rhein J et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis 2008; 46: 1699-701.
85. Jarvis JN, Lawn SD, Vogt M et al. Screening for cryptococcal antigenaemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis 2009; 48: 856-62.
86. Bicanic T, Brouwer AE, Meintjes G et al. Relationship of CSF pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures. AIDS 2009; 23: 701-6.
87. Bicanic T, Wood R, Bekker L-G et al. Antiretroviral roll-out, antifungal roll-back: access to treatment for cryptococcal meningitis. Lancet Infect Dis 2005; 5: 530-1.
88. Loyse A, Thangaraj T, Easterbrook P et al. Cryptococcal meningitis: improving access to essential antifungal medicines in resource poor countries. Lancet Infect Dis 2013; doi: 10.1016/S1473-3099(13)70078-1.
89. Larsen RA, Leal ME, Chan LS et al. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomised trial. Ann Intern Med 1990; 113: 183-7